TrialClinical cancer research : an official journal of the American Association for Cancer Research2016

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Katherine Tarlock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.